

MARKET REPORT



Global Cancer Diagnostics Partnering 2010-2016:
Deal trends, players, financials and forecasts

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts

The Global Cancer Diagnostics Partnering 2010-2016 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer diagnostics partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Cancer diagnostics partnering contract documents

Top cancer diagnostics deals by value

This report provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,170 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announced by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.

Key benefits

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Cancer Diagnostics deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies

Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies

Identify most active Cancer Diagnostics dealmakers since 2010

Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Diagnostics trends and structure of deals entered into by leading companies worldwide.

Cancer Diagnostics Partnering Terms and Agreements includes:

Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2010

Analysis of Cancer Diagnostics deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Cancer Diagnostics deals

Access to Cancer Diagnostics contract documents

Leading Cancer Diagnostics deals by value since 2010

Most active Cancer Diagnostics dealmakers since 2010

In Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,170 Cancer Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Additional Details

Publisher : Current Partnering

Reference : CP22013

Number of Pages : 696

Report Format : PDF

Publisher Information :



Current Partnering
Life science intelligence for destinations

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts [Published by Current Partnering]

- Executive Summary
- Chapter 1 – Introduction
- Chapter 2 – Trends in Cancer Diagnostics dealmaking
 - 2.1. Introduction
 - 2.2. Cancer Diagnostics partnering over the years
 - 2.3. Most active Cancer Diagnostics dealmakers
 - 2.4. Cancer Diagnostics partnering by deal type
 - 2.5. Cancer Diagnostics partnering by therapy area
 - 2.6. Deal terms for Cancer Diagnostics partnering
 - 2.6.1 Cancer Diagnostics partnering headline values
 - 2.6.2 Cancer Diagnostics deal upfront payments
 - 2.6.3 Cancer Diagnostics deal milestone payments
 - 2.6.4 Cancer Diagnostics royalty rates
- Chapter 3 – Leading Cancer Diagnostics deals
 - 3.1. Introduction
 - 3.2. Top Cancer Diagnostics deals by value
- Chapter 4 – Most active Cancer Diagnostics dealmakers
 - 4.1. Introduction
 - 4.2. Most active Cancer Diagnostics dealmakers
 - 4.3. Most active Cancer Diagnostics partnering company profiles
- Chapter 5 – Cancer Diagnostics contracts dealmaking directory
 - 5.1. Introduction
 - 5.2. Cancer Diagnostics contracts dealmaking directory
- Chapter 6 – Cancer Diagnostics dealmaking by technology type
- Chapter 7 – Partnering resource center
 - 7.1. Online partnering
 - 7.2. Partnering events
 - 7.3. Further reading on dealmaking
- Appendices
 - Appendix 1 – Cancer Diagnostics deals by company A-Z
 - Appendix 2 – Cancer Diagnostics deals by stage of development
 - Discovery
 - Preclinical
 - Phase I
 - Phase II
 - Phase III
 - Regulatory
 - Marketed
 - Formulation
 - Appendix 3 – Cancer Diagnostics deals by deal type
 - Asset purchase
 - Assignment
 - Bigpharma outlicensing
 - Co-development
 - Collaborative R&D
 - Co-market
 - Co-promotion
 - CRADA
 - Cross-licensing
 - Development
 - Distribution
 - Equity purchase
 - Evaluation
 - Grant
 - Joint venture
 - Licensing
 - Litigation
 - Manufacturing
 - Marketing
 - Material transfer
 - Option
 - Promotion
 - Research
 - Settlement
 - Spin out
 - Sub-license
 - Supply
 - Technology
 - transfer
 - Termination
 - Warranty
 - Appendix 4 – Cancer Diagnostics deals by therapy area
 - Appendix 5 – Deal type definitions
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent report titles from Current Partnering
- Table of figures
 - Figure 1: Cancer Diagnostics partnering since 2010
 - Figure 2: Active Cancer Diagnostics dealmaking activity– 2010 to 2016
 - Figure 3: Cancer Diagnostics partnering by deal type since 2010
 - Figure 4: Cancer Diagnostics partnering by disease type since 2010
 - Figure 5: Cancer Diagnostics deals with a headline value
 - Figure 6: Cancer Diagnostics deals with an upfront value
 - Figure 7: Cancer Diagnostics deals with a milestone value
 - Figure 8: Cancer Diagnostics deals with a royalty rate value
 - Figure 9: Top Cancer Diagnostics deals by value since 2010
 - Figure 10: Most active Cancer Diagnostics dealmakers 2010 to 2016
 - Figure 11: Online partnering resources
 - Figure 12: Forthcoming partnering events

How to Buy...

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts
[Published by Current Partnering]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/370>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk
or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2995** | Single User Price
- \$4495** | Multi User Price
- \$8995** | Site License Price
- \$14995** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.